Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Obeticholic acid drug shows promise against bile acid diarrhoea

A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms.

21 Oct 2014

New oral biologic medication successfully treats precancerous intestinal inflammation

An oral biologic medication has successfully treated chronic, precancerous inflammation in the intestine, according to results of an animal study authored by an MD/PhD student in the University at Buffalo School of Medicine and Biomedical Sciences.

16 Oct 2014

New research shows impact of ulcerative colitis on patients' quality of life, treatment satisfaction

New research shows that the majority of patients with the challenging inflammatory bowel disease, ulcerative colitis (UC), state that the three biggest impacts of the disease on their lives are on their emotional state (in terms of depression, anger or anxiety levels) (76%), ability to get adequate rest/sleep (75%), and taking sick days off work (70%). Those who have had a colectomy (removal of the colon) were more likely to suffer from these impacts.

14 Oct 2014

Kenneth Rainin Foundation grants $2.2 million for Inflammatory Bowel Disease research

The Kenneth Rainin Foundation announced today that it will grant $2.2 million to scientists to conduct Inflammatory Bowel Disease (IBD) research. The Rainin Foundation offers support for cutting-edge projects that typically are not eligible for funding from more traditional sources due to their ground-breaking, pioneering nature.

14 Oct 2014

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015.

7 Oct 2014

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).

18 Sep 2014

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules.

11 Sep 2014

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

8 Sep 2014

Researchers discover genetic factors involved in development of early-onset ulcerative colitis

UCLA researchers were part of a team that has discovered the interplay of several genetic factors that may be involved in the development of early-onset ulcerative colitis, a severe type of inflammatory bowel disease.

4 Sep 2014

Study: One in every 200 Ontarians diagnosed with inflammatory bowel disease

One in every 200 Ontarians has been diagnosed with inflammatory bowel disease (IBD), with the number of people living with the disease increasing by 64 per cent between 1999 and 2008, according to a study by researchers at the Institute for Clinical Evaluative Sciences, the Children's Hospital of Eastern Ontario, and the Ottawa Hospital Research Institute.

29 Aug 2014

Yale University researchers identify bacterial culprits that drive IBD

Yale University researchers have identified a handful of bacterial culprits that may drive inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, using patients' own intestinal immune responses as a guide.

29 Aug 2014

Study finds a host of new clues on gene-environment interactions in Crohn's disease

A new study finds a wide range of epigenetic changes-alterations in DNA across the genome that may be related to key environmental exposures-in children with Crohn's disease (CD), reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2014

Study shows new role for protein APC in suppressing colorectal cancer

A study recently published in the journal Carcinogenesis by researchers at the University of Kansas shows a new role for the protein adenomatous polyposis coli (APC) in suppressing colorectal cancer - the second-leading cause of cancer-related deaths in the U.S.

22 Aug 2014

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy.

19 Aug 2014

Scientists create computer algorithm for cell and tissue engineering

In a boon to stem cell research and regenerative medicine, scientists at Boston Children's Hospital, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston University have created a computer algorithm called CellNet as a "roadmap" for cell and tissue engineering, to ensure that cells engineered in the lab have the same favorable properties as cells in our own bodies.

16 Aug 2014

23andMe, Pfizer partner to explore genetic factors associated with IBD

23andMe, the leading personal genetics company today announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD.

12 Aug 2014

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc., announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties.

24 Jul 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

People who grow up farm with livestock better protected against inflammatory bowel diseases

New research conducted at Aarhus University has revealed that people who have grown up on a farm with livestock are only half as likely as their urban counterparts to develop the most common inflammatory bowel diseases: ulcerative colitis and Crohn's disease.

14 Jul 2014

Independent testing organization confirms VSL#3 formulation as probiotic product

Probiotics have gained in popularity in recent years and consumers now have many to choose from. However, only 14 of 19 successfully tested through Consumer Lab's quality certification program probiotics.

9 Jul 2014

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Obeticholic acid drug shows promise against bile acid diarrhoea

New oral biologic medication successfully treats precancerous intestinal inflammation

New research shows impact of ulcerative colitis on patients' quality of life, treatment satisfaction

Kenneth Rainin Foundation grants $2.2 million for Inflammatory Bowel Disease research

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Researchers discover genetic factors involved in development of early-onset ulcerative colitis

Study: One in every 200 Ontarians diagnosed with inflammatory bowel disease

Yale University researchers identify bacterial culprits that drive IBD

Study finds a host of new clues on gene-environment interactions in Crohn's disease

Study shows new role for protein APC in suppressing colorectal cancer

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Scientists create computer algorithm for cell and tissue engineering

23andMe, Pfizer partner to explore genetic factors associated with IBD

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

People who grow up farm with livestock better protected against inflammatory bowel diseases

Independent testing organization confirms VSL#3 formulation as probiotic product

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in